Doç. Dr. Musa Barış AYKAN

1. Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

ŞAHİN T. K., Orhan C., Ozercan I. H., Muglu H., Er B., Akyildiz A., et al.

Experimental Hematology and Oncology , cilt.15, sa.1, 2026 (SCI-Expanded, Scopus)

2. Prognostic value of cachexia index in HR +/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors

Keskin G. S. Y., Turgut G. G., Yildirim G., Tuzun E. K., Aslan V., AYKAN M. B., et al.

BMC Cancer , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

3. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

SÜTCÜOĞLU O., Akdoğan O., Onur İ. D., Çiftçi A., Alkan A., Majidova N., et al.

Discover Oncology , cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)

4. Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

Seyyar M., Şancı P. C., Doğan A., Biter S., KÖŞECİ T., Balçık O. Y., et al.

BMC Cancer , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

5. Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort—A Turkish Oncology Group (TOG) Study

Kidi M. M., Asoglu H., Soysal M., KÖŞECİ T., KARA İ. O., ŞAHİN B., et al.

Medicina (Lithuania) , cilt.62, sa.6, 2026 (SCI-Expanded, Scopus)

6. Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure

Kemik F., ŞAHİN T. K., ÖZÇELİK H., Sezer A., BAŞARAN G., Açıkel Yüksel S., et al.

Breast , cilt.87, 2026 (SCI-Expanded, Scopus)

7. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Seyyar M., Kalem A., Sali M., Karabuğa B., ŞAHİN T. K., Dişli A. K., et al.

Current Oncology , cilt.33, sa.6, 2026 (SCI-Expanded, Scopus)

8. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

Seyyar M., Can Şancı P., SAKİN A., Bayramgil A., Dülgar Kaya Ö., SÜNGER E., et al.

Medicina (Lithuania) , cilt.62, sa.5, 2026 (SCI-Expanded, Scopus)

9. Pre-Transplant Prognostic Nutritional Index Independently Predicts Progression-Free Survival After Autologous Stem Cell Transplantation in Lymphoma

Atacan H., Aslan V., Topal A., Mammadzada N., Yıldırım G., Güneysu G. G., et al.

Journal of Clinical Medicine , cilt.15, sa.9, 2026 (SCI-Expanded, Scopus)

10. The Royal Marsden Hospital Score Independently Predicts Overall Survival in Patients with De Novo Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors: A Multicenter Retrospective Analysis

Doğan T., Taş S., Güçlü Kantar T., Karahan İ., Gökçen Demiray A., AYKAN M. B., et al.

Journal of Clinical Medicine , cilt.15, sa.10, 2026 (SCI-Expanded, Scopus)

11. Assessment of Meet-URO and CANLPH Prognostic Models in Metastatic RCC: Insights from a Single-Institution Cohort Predominantly Treated with TKIs

Kuzu Ö. F., KARADURMUŞ N., Kanat N. B., Özel Bozdağ D. İ., Karadurmuş B., Kaplan Tüzün E., et al.

Diagnostics , cilt.16, sa.3, 2026 (SCI-Expanded, Scopus)

12. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

ŞAHİN T. K., Kemik F., Muglu H., Acikgöz Yildiz B., Biter S., Tunbekici S., et al.

Therapeutic Advances in Medical Oncology , cilt.18, 2026 (SCI-Expanded, Scopus)

13. Evaluation of the Efficacy and Safety of FOLFOX in First-Line Treatment of Advanced Pancreatic Cancer

Atacan H., Yildiran Keski̇n G. S., Emi̇n G., Kahraman S., Mammadzade N., Yildirim G., et al.

Journal of Oncological Science , cilt.11, sa.3, ss.211-216, 2025 (Scopus, TRDizin)

14. The Efficacy of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Ewing Sarcoma Patients

Kuzu Ö. F., KARADURMUŞ N., Kanat N. B., Köseoğlu Ç., Dumludağ A., Topal A., et al.

Journal of Clinical Medicine , cilt.14, sa.24, 2025 (SCI-Expanded, Scopus)

15. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

MILDANOĞLU M. M., Kutlu Y., BAŞ O., Koylu B., Dae S. A., SAKİN A., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

16. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer

Sezgin Y., Karhan O., Aldemir M. N., Ürün M., Erçek B. M., Urakcı Z., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

17. The Impact of Clinical and Morphometric Parameters on Hematopoietic Engraftment Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Germ Cell Tumors

Kuzu Ö. F., KARADURMUŞ N., Acar A. G., Kanat N. B., Köseoğlu Ç., Dumludağ A., et al.

Medicina (Lithuania) , cilt.61, sa.9, 2025 (SCI-Expanded, Scopus)

18. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.

Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded, Scopus)

19. Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey

Yildiran Keskin G. S., YETGİNOĞLU Ö., VURĞUN S., Guzel E. Z., Ozkan F. E., Yilmaz M., et al.

Medicina (Lithuania) , cilt.61, sa.6, 2025 (SCI-Expanded, Scopus)

20. Real-world experience with dose-adjusted EPOCH-R in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma: A multicenter analysis from Turkey.

Kidi M. M., BAYRAM E., Soysal M., AYKAN M. B., KARADURMUŞ N., BARIŞTA İ., et al.

Journal of Clinical Oncology , cilt.43, 2025 (SCI-Expanded, Scopus)

21. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Majidova N., YASLIKAYA Ş., MILDANOĞLU M. M., Coskun A., Uzundal D. E., ŞAHİN T. K., et al.

Turkish Journal of Gastroenterology , cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)

22. Is There Any Relationship between Bilateral Pleural Effusion and Blast Crisis in Chronic Myeloid Leukemia?

Erdinç E., AYKAN M. B., Safali M., Arpaci F.

Journal of Oncological Science , cilt.11, sa.1, ss.55-57, 2025 (Scopus, TRDizin)

23. Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer

Bayramgil A., BİLİCİ A., Tatlı A. M., Kahraman S., Altintas Y. E., Akgul F., et al.

Medicina (Lithuania) , cilt.61, sa.2, 2025 (SCI-Expanded, Scopus)

24. Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis

Dökmetaş M., Muğlu H., Özcan E., Bayram Kuvvet B., Helvacı K., Kalacı E., et al.

Medicina (Lithuania) , cilt.61, sa.1, 2025 (SCI-Expanded, Scopus)

25. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

AYKAN M. B., Bölek H., YEKEDÜZ E., Sertesen E., Tural D., Karaçin C., et al.

Therapeutic Advances in Medical Oncology , cilt.17, 2025 (SCI-Expanded, Scopus)

26. Efficacy and Safety of Three Cycles of TIP and Sequential High Dose Chemotherapy in Patients with Testicular Non-Seminomatous Germ Cell Tumors

AYKAN M. B., Yildiran Keskin G., ERTÜRK İ., Acar R., Kose A. F., KARADURMUŞ N.

Journal of Clinical Medicine , cilt.14, sa.1, 2025 (SCI-Expanded, Scopus)

27. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Kahraman S., Hizal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., et al.

BMC Cancer , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)

28. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

Beypınar İ., Demir H., YASLIKAYA Ş., KÖŞECİ T., Demir B., Çolak G., et al.

Breast Cancer Research and Treatment , cilt.208, sa.3, ss.597-604, 2024 (SCI-Expanded, Scopus)

29. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., KARAKAYA S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

30. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

KUTLU Y., Dae S. A., Yilmaz F., Erdem D., Sendur M. A. N., Akbas S., et al.

Cancers , cilt.16, sa.12, 2024 (SCI-Expanded, Scopus)

31. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience

Yildiran Keskin G. S., ERTÜRK İ., AYKAN M. B., Acar R., Dumludag A., Topal A., et al.

Oncology Research and Treatment , cilt.47, sa.6, ss.262-272, 2024 (SCI-Expanded, Scopus)

32. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Yıldırım H. Ç., KUTLU Y., Mutlu E., AYKAN M. B., Korkmaz M., Yalçın S., et al.

International Journal of Clinical Oncology , cilt.29, sa.3, ss.258-265, 2024 (SCI-Expanded, Scopus)

33. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

KARADURMUŞ N., Kaplan M. A., Sendur M. A. N., ÜRÜN Y., Demirci U., Karaca S. B., et al.

Current Medical Research and Opinion , cilt.40, sa.7, ss.1171-1178, 2024 (SCI-Expanded, Scopus)

34. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

GÜVEN D. C., AYKAN M. B., Muglu H., BAYRAM E., Helvaci K., Dursun B., et al.

Cancer Medicine , cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)

35. Efficacy of Perioperative FLOT Therapy in Locally Advanced Gastric Cancer and the Associated Prognostic Factors

Yildiran Keskin G. S., ERTÜRK İ., AYKAN M. B., Acar R., Topal A., Dumludağ A., et al.

Journal of Oncological Science , cilt.10, sa.2, ss.97-104, 2024 (Scopus, TRDizin) Sürdürülebilir Kalkınma

36. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

AYDIN S., Kavak E. E., Topcu A., Bayramgil A., Akgul F., Kahraman S., et al.

Biomolecules and Biomedicine , cilt.23, sa.6, ss.1089-1095, 2023 (Scopus)

37. Parents working as health professionals during the pandemic

BAYRAK AYKAN E., Acavut G., AYKAN M. B.

Journal of Pediatric Nursing , cilt.73, 2023 (SCI-Expanded, SSCI, Scopus)

38. Major and minor salivary gland cancers: A multicenter retrospective study

HACIOĞLU M. B., ERDOĞAN B., Bardakcı M., ALGIN E., Gulbagcı B., Hacibekiroglu I., et al.

Head and Neck , cilt.45, sa.7, ss.1643-1653, 2023 (SCI-Expanded, Scopus)

39. Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkish oncology group study

Acar R., PAYDAŞ S., YILDIRIM M., Kiliçarslan E., ŞAHİN U., DOĞAN A. A., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.8, 2023 (SCI-Expanded, Scopus)

40. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., BAYRAM E., Demirel B. C., et al.

Future Oncology , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded, Scopus)

41. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Erol C., Bardakçi M., Hizal M., Kahraman S., YEKEDÜZ E., GÜVEN D. C., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.72-78, 2023 (Scopus, TRDizin)

42. SEPSIS DUE TO LISTERIA MONOCYTOGENES IN AN IMMUNOCOMPROMISED PATIENT WITH PERITONEAL CARCINOMATOSIS: A CASE REPORT BAĞIŞIKLIĞI BASKILANMIŞ, PERİTONEAL KARSİNOMATOZİSLİ BİR HASTADA LISTERIA MONOCYTOGENES’E BAĞLI SEPSİS: OLGU SUNUMU

Unat İ., TEKİN K., DURMAZ M. O., AYKAN M. B., HOŞBUL T.

Istanbul Tip Fakultesi Dergisi , cilt.86, sa.2, ss.176-179, 2023 (ESCI, Scopus, TRDizin)

43. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations

Kahraman S., Bardakci M., AYKAN M. B., Yasar S., Erol C., Hizal M., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.2, ss.347-354, 2023 (SCI-Expanded, Scopus)

44. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Yıldırım H. Ç., Mutlu E., Chalabiyev E., Özen M., Keskinkılıç M., Ön S., et al.

Breast , cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)

45. Efficacy of ifosfamide, carboplatin and etoposide chemotherapy protocol in relapsed refractory germ cell tumors

AYKAN M. B., ERTÜRK İ., Acar R., Keskin G. S., Örnek E., KARADURMUŞ N.

Gulhane Medical Journal , cilt.64, sa.3, ss.229-234, 2022 (Scopus, TRDizin)

46. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

ÖZDEMİR Ö., Zengel B., Yildiz Y., Uluç B. O., ÇABUK D., Ozden E., et al.

Anti-Cancer Drugs , cilt.33, sa.7, ss.663-670, 2022 (SCI-Expanded, Scopus)

47. Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours

AYKAN M. B., Yildiran G. S., Akcan E., Acar R., ERTÜRK İ., KARADURMUŞ N.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.7, ss.880-884, 2022 (SCI-Expanded, Scopus)

48. The assessment of rheumatologic immune-related adverse events with immune checkpoint inhibitors

TEKGÖZ E., Colak S., Acar R., ERTÜRK İ., AYKAN M. B., Yıldız B., et al.

Gulhane Medical Journal , cilt.64, sa.1, ss.103-109, 2022 (Scopus, TRDizin)

49. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

AYDIN S., Cakan Demirel B., BİLİCİ A., Topcu A., AYKAN M. B., Kahraman S., et al.

Current Medical Research and Opinion , cilt.38, sa.10, ss.1751-1758, 2022 (SCI-Expanded, Scopus)

50. Retrospective Analysis of Testicular Germ Cell Tumor Patients with Brain Metastases: A Single-Center Experience

AYKAN M. B., Yildiran G. S., Acar R., Igret N., Yildiz B., ERTÜRK İ., et al.

Journal of Oncological Science , cilt.8, sa.1, ss.27-33, 2022 (Scopus, TRDizin)

51. High-dose Chemotherapy Response in Adults with Relapsed/Refractory Small Round Cell Tumours

AYKAN M. B., ERTÜRK İ., Acar R., Yildiran G. S., Yildiz B., KARADURMUŞ N.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.1, ss.51-56, 2022 (SCI-Expanded, Scopus)

52. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Esen S. A., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.

Bosnian Journal of Basic Medical Sciences , cilt.22, sa.5, ss.818-825, 2022 (SCI-Expanded, Scopus)

53. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Karacin C., EREN T., Zeynelgil E., İMAMOĞLU G. İ., ALTINBAŞ M., KARADAĞ İ., et al.

Future Oncology , cilt.17, sa.33, ss.4447-4456, 2021 (SCI-Expanded, Scopus)

54. Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation

ERTÜRK İ., KARADURMUŞ N., Kızıloz H., ACAR R., YILDIZ B., AYKAN M. B., et al.

Journal of Oncology Pharmacy Practice , cilt.27, sa.7, ss.1657-1664, 2021 (SCI-Expanded, Scopus)

55. Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; A new entity

KÜÇÜKARDA A., Sayln S., Gokyer A., AYKAN M. B., KARADURMUŞ N., Cicin I.

Immunotherapy , cilt.13, sa.7, ss.565-570, 2021 (SCI-Expanded, Scopus)

56. Clinical presentation and course of the novel coronavirus disease 2019 in patients with various types of cancer: A retrospective case-control analysis of an experienced cancer center in Turkey

Acar R., YILMAZ TEHLİ G., SAVAŞÇI Ü., AYKAN M. B., Kiziloz H., CÜCE F., et al.

Journal of Cancer Research and Therapeutics , cilt.17, sa.2, ss.556-564, 2021 (SCI-Expanded, Scopus)

57. Retrospective analysis of patients with relapsed/refractory medulloblastoma after autologous stem cell transplantation

Acar R., ERTÜRK İ., Kizilöz H., Okçelik S., Yildiz B., AYKAN M. B., et al.

Gulhane Medical Journal , cilt.62, sa.4, ss.266-271, 2020 (Scopus, TRDizin)

58. Gemcitabine, oxaliplatin and paclitaxel (Gempox) in patients with relapsed or refractory germ cell tumors after high dose chemotherapy, a retrospective single-center experience

Acar R., ERTÜRK İ., Kiziloz H., Okcelik S., Yildiz B., AYKAN M. B., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.30, sa.4, ss.191-196, 2020 (SCI-Expanded, Scopus, TRDizin)

59. Comparison of anthropometric measurements for prediction of the atherosclerosis and liver histology in young adults with nonalcoholic fatty liver disease

Dogan T., Ozturk K., Celikkanat S., AYKAN M. B., UYGUN A.

European Journal of Gastroenterology and Hepatology , cilt.31, sa.11, ss.1460-1466, 2019 (SCI-Expanded, Scopus)

60. Interpretation of blood apelin level across different clinical pictures of diabetes mellitus

AYKAN M. B., Tasci I.

Diabetes Research and Clinical Practice , cilt.152, ss.183-184, 2019 (SCI-Expanded, Scopus)

61. Inflammation and aortic pulse wave velocity: A multicenter longitudinal study in patients with inflammatory bowel disease

Zanoli L., Ozturk K., Cappello M., Inserra G., Geraci G., Tuttolomondo A., et al.

Journal of the American Heart Association , cilt.8, sa.3, 2019 (SCI-Expanded, Scopus)

62. Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with reduced/mid-range ejection fraction via vegf and svegfr-1

ERTÜRK İ., SAĞLAM K., Elasan S., AYKAN M. B., Acar R., YEŞİLDAL F., et al.

Saudi Medical Journal , cilt.39, sa.10, ss.1028-1034, 2018 (SCI-Expanded, Scopus)

63. Seizure induced by ertapenem in an elderly patient with dementia

Aydin A., AYKAN M. B., SAĞLAM K.

Consultant Pharmacist , cilt.32, sa.10, ss.561-562, 2017 (Scopus)

64. Morvan Syndrome: A rare cause of syndrome of inappropriate antidiuretic hormone secretion

Demirbas S., AYKAN M. B., Zengin H., Mazman S., SAĞLAM K.

Clujul Medical , cilt.90, sa.3, ss.353-355, 2017 (Scopus)

65. Acquired leukocyte inclusion bodies resembling döhle bodies during acute cholangitis Akut kolanjit seyrinde lökositlerde döhle benzeri edinsel ınklüzyonlar

Özgür G., AYKAN M. B., YILDIRIM M., Sayın S., UYGUN A., Beyan C.

Turkish Journal of Hematology , cilt.34, sa.4, ss.359-360, 2017 (SCI-Expanded, Scopus, TRDizin)

66. Comment on ‘Novel anticoagulants – an update on the latest developments and management for clinicians treating patients on these drugs’

AYKAN M. B., Arslan E., Demirbas S., SAĞLAM K.

Journal of Oral Pathology and Medicine , cilt.45, sa.8, ss.634, 2016 (SCI-Expanded, Scopus)

67. Comment on "the relationship of recurrent aphthous stomatitis and Helicobacter pylori, cytokine gene polymorphism and cobalamin"

Arslan E., AYKAN M. B., Saʇlam K.

Turkish Journal of Gastroenterology , cilt.27, sa.1, ss.87, 2016 (SCI-Expanded, Scopus, TRDizin)

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (TrDizin)

H-İndeks (TrDizin)

Atıf (Diğer Toplam)

Proje

Açık Erişim